Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult ...

GSK’s share price has been pressured recently from several negative events, but this may leave a bargain to be had. I've ...

Last week's rumour that GSK was poised to make a bid to acquire IDRx and its experimental targeted therapy for a rare form of rare gastrointestinal cancer was on the money. This morning ...

Recently, GSK agreed to acquire IDRx, Inc., a biopharmaceutical company focused on precision therapeutics for gastrointestinal stromal tumors, for $1 billion. Price Action: GSK stock is up 0.76% ...

In pancreatic cancer, pelareorep previously demonstrated a strong efficacy signal when administered with gemcitabine, nab-paclitaxel and atezolizumab. Our new safety data indicate its ability to also ...

The aging population and lifestyle-related factors contribute to a surge in pancreatic cancer cases. The aggressive nature of the disease and its high mortality rate demand innovative therapies.

GSK’s Jemperli is designed to help the body’s immune system find and attack cancer cells, and is already approved in the EU ...

GSK is reportedly in late-stage negotiations about a $1 billion deal to acquire IDRx and its experimental targeted therapy for a form of rare gastrointestinal stromal tumour (GIST). The rumoured ...

The stock market can be a scary place for those who aren’t prepared. Our writer outlines three ways we might avoid getting caught out.

We’re thrilled to announce that IDRx has entered into an agreement to be acquired by GSK for up to $1.15 billion. This includes our lead molecule, IDRX-42, a highly selective KIT TKI in clinical ...